Skip to search formSkip to main contentSkip to account menu

Ranexa

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Extended-release ranolazine (ranolazine ER) (Ranexa) is an antianginal agent that achieves its effects via a novel mechanism of… 
2010
2010
We report the case of a renal transplant patient on tacrolimus who developed a fully reversible renal failure and a doubling in… 
2008
2008
Ranolazine [Ranexa; (±)-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine] is novel anti-ischemic… 
2007
2007
Ranolazine will provide a small benefit in symptom control in patients with chronic angina and persistent symptoms despite… 
2007
2007
(1) Ranolazine-- an adjunctive treatment to beta-blockers, calcium channel blockers, or long-acting nitrates-- is indicated for… 
2005
2005
CV Therapeutics, under license from Roche (formerly Syntex), is developing ranolazine (Ranexa), a metabolic modulator and a…